Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-27T05:29:09.695Z Has data issue: false hasContentIssue false

21a - New Efforts towards Evidence-Informed Practice and Practice-Informed Research: Commentary on Recent Developments in the Pharmacologic Management of Personality Disorders

from Part V - Treatment

Published online by Cambridge University Press:  24 February 2020

By
Jutta Stoffers-Winterling  and
Klaus Lieb
Edited by
Carl W. Lejuez  and
Kim L. Gratz
Carl W. Lejuez
Affiliation:
University of Kansas
Kim L. Gratz
Affiliation:
University of Toledo, Ohio
Get access

Summary

This commentary focuses on the current state and recent developments within the field of research on drug treatments for borderline personality disorder. From an evidence-based medicine perspective, the relevance of the currently available evidence for clinical practice is critically discussed. Some research/practice gaps are highlighted, like polypharmacy and the widespread use of quetiapine, which both lack supporting, sufficiently reliable evidence. Sources for the lack of practically relevant research are outlined, and the example of recent research on Olanzapine for patients with borderline personality disorder is amplified. Last, new initiatives are presented which aim at improving the value of research, like the REWARD alliance, the AllTrials campaign, and the James Lind alliance that guide, inform, and support the design, conduct, and publication of studies that are of relevancy to consumers and clinicians, and have the potential to transform healthcare. Some first encouraging results of these endeavors are presented.

Keywords

borderline personality disorderpharmacotherapydrug therapyCochrane Collaborationtreatmentapplicabilitygeneralizabilityevidence-based medicineREWARD allianceEQUATOR network
Type
Chapter
Information
The Cambridge Handbook of Personality Disorders , pp. 514 - 516
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

ACTRN12615000705583. (n.d.). Evaluation of quetiapine as an adjunct treatment to psychotherapy for borderline personality disorder. Retrieved September 16, 2018, from www.anzctr.org.au/ACTRN12615000705583.aspxGoogle Scholar
ACTRN12616001192471. (n.d.). VERBATIM: A randomised controlled trial of aripiprazole for the treatment of auditory verbal hallucinations in borderline personality disorder. Retrieved September 16, 2018, from www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371038Google Scholar
EudraCT Number 2012-003136-23. (n.d.). EudraCT Number 2012-003136-23 – Clinical trial results – EU Clinical Trials Register. Retrieved August 14, 2018, from www.clinicaltrialsregister.eu/ctr-search/trial/2012-003136-23/resultsGoogle Scholar
NCT00254748. (n.d.). Verkes Borderline Study: The effect of quetiapine on borderline personality disordered patients. Retrieved September 16, 2018, from https://ClinicalTrials.gov/show/NCT00254748Google Scholar
Black, D. W., Zanarini, M. C., Romine, A., Shaw, M., Allen, J., & Schulz, S. C. (2014). Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: A randomized, double-blind, placebo-controlled trial. American Journal of Psychiatry, 171(11), 1174–1182.Google Scholar
Bozzatello, P., Rocca, P., Uscinska, M., & Bellino, S. (2017). Efficacy and tolerability of asenapine compared with olanzapine in borderline personality disorder: An open-label randomized controlled trial. CNS Drugs, 31(9), 809–819.Google Scholar
Bridler, R., Häberle, A., Müller, S. T., Cattapan, K., Grohmann, R., Toto, S., … Greil, W. (2015). Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 25(6), 763–772.CrossRefGoogle ScholarPubMed
Brown, T. (2013). It’s time for AllTrials registered and reported. In The Cochrane Collaboration (Ed.), Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons. https://doi.org/10.1002/14651858.ED000057Google Scholar
Chalmers, I., & Glasziou, P. (2009). Avoidable waste in the production and reporting of research evidence. Lancet, 374(9683), 86–89.Google Scholar
Crawford, M. J., Sanatinia, R., Barrett, B., Byford, S., Cunningham, G., Gakhal, K., … Reilly, J. G. (2015). Lamotrigine versus inert placebo in the treatment of borderline personality disorder: Study protocol for a randomized controlled trial and economic evaluation. Trials, 16, 308. https://doi.org/10.1186/s13063–015-0823-xGoogle Scholar
Crawford, M. J., Sanatinia, R., Barrett, B., Cunningham, G., Dale, O., Ganguli, P., … Reilly, J. G. (2018a). The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: A randomized placebo-controlled trial. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2018.17091006CrossRefGoogle Scholar
Crawford, M. J., Sanatinia, R., Barrett, B., Cunningham, G., Dale, O., Ganguli, P., … Reilly, J. G. (2018b). Lamotrigine for people with borderline personality disorder: A RCT. Health Technology Assessment (Winchester, England), 22(17), 1–68. https://doi.org/10.3310/hta22170.Google Scholar
De Angelis, C., Drazen, J. M., Frizelle, F. A., Haug, C., Hoey, J., Horton, R., … International Committee of Medical Journal Editors (2004). Clinical trial registration: A statement from the International Committee of Medical Journal Editors. The New England Journal of Medicine, 351(12), 1250–1251.CrossRefGoogle ScholarPubMed
Gunderson, J. G., & Choi-Kain, L. W. (2018). Medication management for patients with borderline personality disorder. American Journal of Psychiatry, 175(8), 709–711.Google Scholar
Jariani, M., Saaki, M., Nazari, H., & Birjandi, M. (2010). The effect of olanzapine and sertraline on personality disorder in patients with methadone maintenance therapy. Psychiatria Danubina, 22(4), 544–547.Google Scholar
Macleod, M. R., Michie, S., Roberts, I., Dirnagl, U., Chalmers, I., Ioannidis, J. P. A., … Glasziou, P. (2014). Biomedical research: Increasing value, reducing waste. Lancet, 383(9912), 101–104.CrossRefGoogle ScholarPubMed
National Health and Medical Research Council, Canberra, Australia [NHMRC]. (2013). Clinical Practice Guideline for the Management of Borderline Personality Disorder. Retrieved August 27, 2018 from www.nhmrc.gov.au/guidelines/publications/mh25.Google Scholar
National Institute for Health and Care Excellence, UK [NICE]. (2009). NICE Clinical Guideline 78. Borderline Personality Disorder: Treatment and Management. Full Guideline (January 2009). Retrieved August 27, 2018 from www.nice.org.uk/guidance/cg78.Google Scholar
Nickel, M. K., Muehlbacher, M., Nickel, C., Kettler, C., Pedrosa, G. F., Bachler, E., … Kaplan, P. (2006). Aripiprazole in the treatment of patients with borderline personality disorder: A double-blind, placebo-controlled study. American Journal of Psychiatry, 163(5), 833–838.Google Scholar
Petit-Zeman, S., Firkins, L., & Scadding, J. W. (2010). The James Lind Alliance: Tackling research mismatches. Lancet, 376(9742), 667–669.CrossRefGoogle Scholar
Reich, D. B., Zanarini, M. C., & Bieri, K. A. (2009). A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. International Clinical Psychopharmacology, 24(5), 270–275.Google ScholarPubMed
Sackett, D. L., Rosenberg, W. M., Gray, J. A., Haynes, R. B., & Richardson, W. S. (1996). Evidence based medicine: What it is and what it isn’t. BMJ, 312(7023), 71–72.CrossRefGoogle ScholarPubMed
Shafti, S., & Kaviani, H. (2015). A comparative study on olanzapine and aripiprazole for symptom management in female patients with borderline personality disorder. Klinik Psikofarmakoloji Bülteni/Bulletin of Clinical Psychopharmacology, 25(1), 38–43.Google Scholar
Shafti, S., & Shahveisi, B. (2010). Olanzapine versus haloperidol in the management of borderline personality disorder: A randomized double-blind trial. Journal of Clinical Psychopharmacology, 30(1), 44–47.CrossRefGoogle ScholarPubMed
Simera, I., Moher, D., Hirst, A., Hoey, J., Schulz, K. F., & Altman, D. G. (2010). Transparent and accurate reporting increases reliability, utility, and impact of your research: Reporting guidelines and the EQUATOR Network. BMC Medicine, 8, 24. https://doi.org/10.1186/1741-7015-8-24CrossRefGoogle ScholarPubMed
Stoffers, J. M., & Lieb, K. (2015). Pharmacotherapy for borderline personality disorder: Current evidence and recent trends. Current Psychiatry Reports, 17(1), 534–545.CrossRefGoogle ScholarPubMed
Stoffers, J., Völlm, B. A., Rucker, G., Timmer, A., Huband, N., & Lieb, K. (2010). Pharmacological interventions for borderline personality disorder. Cochrane Database of Systematic Reviews, 6 [CD005653]. https://doi.org/10.1002/14651858.CD005653.pub2Google Scholar
Stoffers‐Winterling, J. M., Storebø, O. J., Völlm, B. A., Mattivi, J. T., Nielsen, S. S., Kielsholm, M. L., … Lieb, K. (2018). Pharmacological interventions for people with borderline personality disorder. Cochrane Database of Systematic Reviews, 2. https://doi.org/10.1002/14651858.CD012956Google Scholar
Tritt, K., Nickel, C., Lahmann, C., Leiberich, P. K., Rother, W. K., Loew, T. H., & Nickel, M. K. (2005). Lamotrigine treatment of aggression in female borderline-patients: A randomized, double-blind, placebo-controlled study. Journal of Psychopharmacology, 19(3), 287–291.Google Scholar
Zanarini, M. C., Frankenburg, F. R., & Parachini, E. A. (2004). A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Journal of Clinical Psychiatry, 65(7), 903–907.Google Scholar
Zanarini, M. C., Frankenburg, F. R., Reich, D. B., Harned, A. L., & Fitzmaurice, G. M. (2015). Rates of psychotropic medication use reported by borderline patients and Axis II Comparison subjects over 16 years of prospective follow-up. Journal of Clinical Psychopharmacology, 35(1), 63–67.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×